dm+d

Unassigned

New Medicines

Erythropoietic protoporphyria (EPP) in adults - first-line

Information

New molecular entity
Mitsubishi Tanabe
Mitsubishi Tanabe

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

Stimulates melanocyte receptor MC1R
EPP affects between 1 in 50,000 to 75,000 people [1].
Erythropoietic protoporphyria (EPP) in adults - first-line
Oral